Daily Newsletter

11 September 2023

Daily Newsletter

11 September 2023

Brainomix and TIPAL partner to assess e-Lung platform

The platform helps standardise the quantification of lung fibrosis on high resolution CT scans to detect progressive fibrosis.

RanjithKumar Dharma September 11 2023

Brainomix is set to partner with the TIPAL trial group to assess its e-Lung platform, an artificial intelligence-powered image processing module and tool.

The partnership will carry out a sub-study to evaluate the efficacy of the platform.

The TIPAL trial is a placebo-controlled, 52-week, multi-centre study that assesses the impacts of lansoprazole and will involve 298 patients who will conduct home spirometry tests to measure their forced vital capacity.

Lansoprazole is a medication prescribed for heartburn, indigestion and acid reflux, in patients diagnosed with idiopathic pulmonary fibrosis.

The Brainomix sub-study will be conducted in parallel by leveraging its e-Lung platform.

The platform helps standardise the quantification of lung fibrosis on high-resolution CT scans for precisely identifying patients with progressive fibrosis.

Meanwhile, this platform focuses on an imaging biomarker, the weighted reticulovascular (WRV) score.

This score quantifies the extent to which reticulovascular abnormalities affect the lung and has proven to offer better prognostic value against traditional measures.

Determining the difference in change in WRV score between lansoprazole treatment and placebo is the primary aim of the sub-study.

TIPAL chief investigator professor Andrew Wilson said: “It is great to have the chance to incorporate the cutting-edge CT scanning technology developed by Brainomix into the TIPAL study.

“Not only will this venture tell whether lansoprazole improves the scarring detected on CT scans, but it will allow us to compare CT scan abnormalities to home-based lung function tests.”

The Norfolk and Norwich University Hospitals NHS Foundation Trust sponsored the TIPAL trial, which is funded by the National Institute of Health Research.

Generative AI set to transform the medical devices industry

Generative AI can improve personalized healthcare by collecting data from patients via wearable devices, which can provide continuous, real-time data that can complement traditional data sources such as imaging, patient records, and more. It can also enhance existing imaging techniques by generating high-quality images of organs using data from low-resolution images (such as ultrasounds). However, the collection and use of patient healthcare data through AI medical products could conflict with regulations around the globe.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close